Briacell Gross Profit from 2010 to 2024

BCTX Stock

USD 0.84 0.09 12.00%

Briacell Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Briacell Therapeutics Corp makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-82.6 K

Current Value

-78.5 K

Quarterly Volatility

23.2 K

Credit Downgrade

Yuan Drop

Covid

Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 86.7 K, Interest Expense of 0.0 or Other Operating Expenses of 34.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.

Check out the analysis of Briacell Therapeutics Correlation against competitors.

Latest Briacell Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Briacell Therapeutics Corp over the last few years. Gross profit is a required income statement account that reflects total revenue of Briacell Therapeutics Corp minus its cost of goods sold. It is profit before Briacell Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Briacell Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Briacell Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Briacell Gross Profit Regression Statistics

	Arithmetic Mean	(23,315)
	Coefficient Of Variation	(99.69)
	Mean Deviation	15,254
	Median	(14,273)
	Standard Deviation	23,243
	Sample Variance	540.2M
	Range	68.6K
	R-Value	(0.60)
	Mean Square Error	372.8M
	R-Squared	0.36
	Significance	0.02
	Slope	(3,115)
	Total Sum of Squares	7.6B

Briacell Gross Profit History

	2024	-78.5 K
	2023	-82.6 K
	2022	-15.5 K
	2021	-15.1 K
	2020	-15.6 K
	2019	-14 K

Other Fundumenentals of Briacell Therapeutics

Gross Profit Margin

Briacell Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Receivables	Short Term Investments	Intangible Assets	Net Tangible Assets	Current Deferred Revenue	Net Invested Capital	Long Term Investments	Net Working Capital	Common Stock	Short Long Term Debt	Capital Stock	Short Term Debt	Long Term Debt	Capital Surpluse
Total Assets		0.79	-0.98	-0.33	-0.05	0.52	0.98	0.02	-0.45	0.42	0.84	-0.44	0.79	-0.08	0.97	0.69	-0.51	0.69	-0.51	-0.71	0.06
Total Stockholder Equity	0.79		-0.8	0.18	-0.22	-0.1	0.77	-0.26	-0.16	0.17	0.89	-0.13	0.98	-0.2	0.78	0.25	-0.17	0.24	-0.17	-0.31	0.19
Net Debt	-0.98	-0.8		0.24	0.15	-0.49	-1.0	0.09	0.41	-0.43	-0.84	0.42	-0.83	0.17	-0.99	-0.64	0.49	-0.63	0.49	0.65	-0.16
Retained Earnings	-0.33	0.18	0.24		-0.76	-0.7	-0.3	-0.86	0.62	-0.52	-0.23	0.65	0.13	-0.71	-0.2	-0.87	0.74	-0.88	0.74	0.87	0.66
Accounts Payable	-0.05	-0.22	0.15	-0.76		0.1	-0.11	0.96	-0.36	0.21	0.13	-0.36	-0.19	0.99	-0.23	0.51	-0.44	0.54	-0.44	-0.6	-0.94
Total Liab	0.52	-0.1	-0.49	-0.7	0.1		0.54	0.27	-0.45	0.42	0.1	-0.48	-0.07	0.03	0.51	0.75	-0.54	0.74	-0.54	-0.65	-0.01
Total Current Assets	0.98	0.77	-1.0	-0.3	-0.11	0.54		-0.04	-0.43	0.45	0.84	-0.45	0.8	-0.14	0.99	0.69	-0.52	0.68	-0.52	-0.69	0.13
Net Receivables	0.02	-0.26	0.09	-0.86	0.96	0.27	-0.04		-0.41	0.29	0.15	-0.45	-0.23	0.93	-0.15	0.62	-0.53	0.65	-0.53	-0.69	-0.89
Short Term Investments	-0.45	-0.16	0.41	0.62	-0.36	-0.45	-0.43	-0.41		-0.52	-0.36	0.6	-0.18	-0.34	-0.34	-0.62	0.81	-0.62	0.81	0.62	0.32
Intangible Assets	0.42	0.17	-0.43	-0.52	0.21	0.42	0.45	0.29	-0.52		0.37	-0.98	0.26	0.23	0.38	0.58	-0.8	0.57	-0.8	-0.55	-0.21
Net Tangible Assets	0.84	0.89	-0.84	-0.23	0.13	0.1	0.84	0.15	-0.36	0.37		-0.38	0.92	0.13	0.81	0.58	-0.45	0.58	-0.45	-0.65	-0.12
Current Deferred Revenue	-0.44	-0.13	0.42	0.65	-0.36	-0.48	-0.45	-0.45	0.6	-0.98	-0.38		-0.21	-0.37	-0.37	-0.68	0.88	-0.67	0.88	0.66	0.35
Net Invested Capital	0.79	0.98	-0.83	0.13	-0.19	-0.07	0.8	-0.23	-0.18	0.26	0.92	-0.21		-0.18	0.81	0.3	-0.23	0.29	-0.23	-0.36	0.17
Long Term Investments	-0.08	-0.2	0.17	-0.71	0.99	0.03	-0.14	0.93	-0.34	0.23	0.13	-0.37	-0.18		-0.25	0.47	-0.45	0.5	-0.45	-0.57	-0.95
Net Working Capital	0.97	0.78	-0.99	-0.2	-0.23	0.51	0.99	-0.15	-0.34	0.38	0.81	-0.37	0.81	-0.25		0.61	-0.42	0.59	-0.42	-0.6	0.24
Common Stock	0.69	0.25	-0.64	-0.87	0.51	0.75	0.69	0.62	-0.62	0.58	0.58	-0.68	0.3	0.47	0.61		-0.78	1.0	-0.78	-0.96	-0.37
Short Long Term Debt	-0.51	-0.17	0.49	0.74	-0.44	-0.54	-0.52	-0.53	0.81	-0.8	-0.45	0.88	-0.23	-0.45	-0.42	-0.78		-0.78	1.0	0.78	0.42
Capital Stock	0.69	0.24	-0.63	-0.88	0.54	0.74	0.68	0.65	-0.62	0.57	0.58	-0.67	0.29	0.5	0.59	1.0	-0.78		-0.78	-0.97	-0.41
Short Term Debt	-0.51	-0.17	0.49	0.74	-0.44	-0.54	-0.52	-0.53	0.81	-0.8	-0.45	0.88	-0.23	-0.45	-0.42	-0.78	1.0	-0.78		0.78	0.42
Long Term Debt	-0.71	-0.31	0.65	0.87	-0.6	-0.65	-0.69	-0.69	0.62	-0.55	-0.65	0.66	-0.36	-0.57	-0.6	-0.96	0.78	-0.97	0.78		0.53
Capital Surpluse	0.06	0.19	-0.16	0.66	-0.94	-0.01	0.13	-0.89	0.32	-0.21	-0.12	0.35	0.17	-0.95	0.24	-0.37	0.42	-0.41	0.42	0.53

Click cells to compare fundamentals

About Briacell Therapeutics Financial Statements

Briacell Therapeutics investors use historical fundamental indicators, such as Briacell Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Briacell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	-82.6 K	-78.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC